In vivo experiments confirmed that blocking HCAR1/β‐Arrestin2/PP2A signaling axis suppressed tumor growth and metastasis, and augmented the therapeutic efficacy of cisplatin. The gene discussed is HCAR1; the disease is neoplasm.